Clinical trials by Bang and Slamon have found that when trastuzumab is used in combination with chemotherapy to treat HER2-positive breast and gastric cancer patients, the objective response rate (ORR) is about 50%, and the median overall survival (mOS) exceeds 1-2 years (14, 18). Here, ERBB2 is linked to gastric cancer.